Dara Wright - 16 Dec 2022 Form 4 Insider Report for BIO-RAD LABORATORIES, INC. (BIO)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
19 Dec 2022, 10:52:44 UTC
Prior SEC filing
07 Sep 2022
Next SEC filing
06 Sep 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Dara Wright
Filing notes and source

Key filing fact

Dara Wright filed Form 4 for BIO-RAD LABORATORIES, INC. (BIO) on 19 Dec 2022.

Key facts

  • This page summarizes Dara Wright's Form 4 filing for BIO-RAD LABORATORIES, INC. (BIO).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 19 Dec 2022, 10:52.

Change

  • Previous filing in this sequence was filed on 07 Sep 2022.
  • Current net transaction value: -$92,203.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BIO transaction

Bio-Rad A Common Stock

Options Exercise

Transaction value
$0
Shares
+502
Change %
+34%
Price
$0.000000
Shares after
1,988
Date
16 Dec 2022
Ownership
Direct
Footnotes
F1, F2
BIO transaction

Bio-Rad A Common Stock

Tax liability

Transaction value
-$92,203
Shares
-226
Change %
-11%
Price
$407.98
Shares after
1,762
Date
16 Dec 2022
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-502
Change %
-33%
Price
$0.000000
Shares after
1,005
Date
16 Dec 2022
Ownership
Direct
Underlying class
Bio-Rad A Common Stock
Underlying amount
502
Exercise price
$0.000000
Footnotes
F3, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Shares of Class A common stock acquired on the vesting of restricted stock units.

Footnote F2

Includes 26.0150 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 09/30/2022.

Footnote F3

Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

Footnote F4

On December 16, 2019, the reporting person was granted 2,511 restricted stock units, vesting in 5 equal annual installments beginning on the first anniversary of the grant date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .